SITC 29th Annual Meeting: Concurrent Session - Immunopotentiation by Radiotherapy - Mechanisms and OpportunitiesNovember 7-9, 2014Gaylord National Hotel & Convention Center National Harbor, MDSession Co-Chairs Sandra Demaria, MD – New York University Susan Knox, MD, PhD – Stanford University SITC 29th Annual Meeting Organizers Arthur A. Hurwitz, PhD - National Cancer Institute Kim A. Margolin, MD - Stanford University Daniel E. Speiser, MD - Ludwig Center for Cancer Research of the University of Lausanne Walter J. Urba, MD, PhD - Earle A. Chiles Research InstituteProgram SummaryRadiotherapy is a mainstay of cancer treatment and has been used for a long time to achieve local tumor control. Experimental data from multiple cancer models has demonstrated that tumor cell death induced by ionizing radiation can be immunogenic and promote cross-priming of anti-tumor T cells. Radiation also modifies the tumor microenvironment into an immune active site, effectively converting the tumor into an in situ vaccine. These properties of radiotherapy suggest that it can be an optimal partner for immunotherapy. Pre-clinical data and some clinical observations support this hypothesis. This session at the 29th Annual Meeting on November 7, 2014 in National Harbor, MD focused on novel opportunities for improving tumor responses to treatment by combining radiotherapy with immunotherapy. Mechanisms underlying the synergy between radiotherapy and different immunotherapy agents was also discussed. About the SITC 29th Annual MeetingThe SITC 29th Annual Meeting provided a multidisciplinary educational and interactive environment focused on improving outcomes for current and future patients with cancer by incorporating strategies based on basic and applied cancer immunotherapy. The meeting consisted of cutting-edge research presentations by experts in the field, oral and poster abstract presentations, and ample opportunities for structured and informal discussions, including important networking opportunities. In addition, the meeting included updates on major national and international initiatives coming from academia, government and industry, as well as important society projects. #ClinicalTrials #BreastCancers #Melanoma #PresentationSlides #Video #AnnualMeeting #SITC#CombinationTherapy #Cytokines #ImmuneCheckpointInhibitors #Vaccines #Clinician #Industry #Oncologist #Researcher #2014
Meeting: SITC 29th Annual Meeting; Session: Concurrent Session — Immunopotentiation by Radiotherapy: Mechanisms and Opportunities; Presentation: Radiotherapy with TGF-β Blockade Jump-Starts Tumor-Specific T Cells and Immune Checkpoint Inhibitors Keep Them Going; Presenter: Sandra Demaria, MD – New York University; Date: November 7, 201400:21:47
Meeting: SITC 29th Annual Meeting; Session: Concurrent Session — Immunopotentiation by Radiotherapy: Mechanisms and Opportunities; Presentation: The Anti-Tumor Immune Response Generated by Radiation Therapy May be Limited by Tumor Cell Adaptive Resistance and can be Circumvented by PD-L1 Blockade; Presenter: Simon Dovedi, PhD, MSc, BSC – University of Manchester; Date: November 7, 201400:15:34
Meeting: SITC 29th Annual Meeting; Session: Concurrent Session — Immunopotentiation by Radiotherapy: Mechanisms and Opportunities; Presentation: CD47 Limits Cooperation between Adaptive Tumor Immunity and Radiation Therapy; Presenter: David D. Roberts, PhD – National Cancer Institute; Date: November 7, 201400:16:03